Back to CITADEL ADVISORS LLC CITADEL ADVISORS LLC

EPRXEPRX
5 quarters

Position history for CITADEL ADVISORS LLCCITADEL ADVISORS LLC's holdings in EUPRAXIA PHARMACEUTICALS INC

CITADEL ADVISORS LLC holds 502,011 shares of EPRX (EUPRAXIA PHARMACEUTICALS INC), worth $3.3M as of 2026-Q2. The position was increased (+118.1% shares). EPRX represents 0.0% of CITADEL ADVISORS LLC's portfolio.

Current Value

$3.3M

Current Shares

502,011

Total Value Change

+$3.3M

Total Shares Change

+489,957

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Increased
502,011
+118.1%
$3.3M0.0%$6.61
43
2026-Q1
New
230,176
-
$1.7M0.0%$8.02
36
2025-Q3
Exited
0
-100.0%
$00.0%$5.75
0
2025-Q2
Increased
18,236
+51.3%
$107,9570.0%$5.30
21
2025-Q1
New
12,054
-
$39,4170.0%$3.38
31

Other major holders of EPRX: BALYASNY ASSET MANAGEMENT L.P., SCOTIA CAPITAL INC.

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used